首页> 外文OA文献 >PCN14 AN INDIRECT COMPARISON OF THE EFFICACY OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) OR BEVACIZUMAB PLUS CARBOPLATIN AND PACLITAXEL (BCP) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)

【2h】

PCN14 AN INDIRECT COMPARISON OF THE EFFICACY OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) OR BEVACIZUMAB PLUS CARBOPLATIN AND PACLITAXEL (BCP) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)

机译：PCN14在患有癌或癌前病变的单发性癌患者中，贝伐单抗+西西他汀和吉西他滨（BCG）或贝伐单抗+卡铂和多西他塞（BCP）对比西妥昔单抗+长春瑞滨和西沙汀（CVC）在单发性癌前癌患者中的疗效差NSCLC）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Walzer S; de Castro Carpeño J; Vergnenegre A; Chouaid C; Heigener D; Bischoff HG; Aultman R; Siebert U;
展开▼
作者单位

展开▼
年度 2009
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. 9164 An indirect comparison of the efficacy of bevacizumab plus cisplatin and gemcitabine (BCG) or bevacizumab plus carboplatin and paclitaxel (BCP) versus pemetrexed plus cisplatin (PC) and cetuximab plus vinorelbine and cisplatin (CVC) in patients (pts) with advanced or recurrent non-small cell cancer (NSCLC) [J] . S.Walzer, J.de Castro Carpeno, A.V.Vergnenegre, European Journal of Cancer Supplements . 2009,第2期

机译：9164贝伐单抗加顺铂和吉西他滨（BCG）或贝伐单抗加卡铂和紫杉醇（BCP）与培美曲塞加顺铂（PC）和西妥昔单抗加长春瑞滨和顺铂（CVC）的间接疗效比较非小细胞癌（NSCLC）
2. An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer [J] . NuijtenM.J.C., AultmanR., CarpeoJ.D.C., Current medical research and opinion . 2011,第11期

机译：贝伐单抗联合卡铂和紫杉醇与培美曲塞联合顺铂在晚期或复发性非鳞状腺癌非小细胞肺癌患者中的间接疗效比较
3. 6503 ORAL Efficacy and safety results from BO17704, a randomised, placebo-controlled phase III study of bevacizumab in combination with cisplatin and gemcitabine in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) [J] . C.Manegold, J.vonPawel, P.Zatloukal, European Journal of Cancer Supplements . 2007,第4期

机译：6503口服功效的有效性和安全性来自BO17704，这是一项贝伐单抗联合顺铂和吉西他滨对晚期或复发性非鳞状非小细胞肺癌（NSCLC）患者进行的随机，安慰剂对照的III期临床研究
4. Pemetrexed versus docetaxel single agent chemotherapy in chemotherapy-naive elderly patients with advanced non-small cell lung cancer [C] . Hua Xin, Zhenguo Han, Haibo Huang 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
5. Phase II Trial of Carboplatin Paclitaxel Cetuximab and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Non-Squamous Non-Small Cell Lung Cancer: SWOG S0536 [O] . Edward S. Kim, James Moon, Roy S. Herbst, -1

机译：在晚期非鳞状非小细胞肺癌中卡铂紫杉醇西妥昔单抗和贝伐单抗的第二阶段试验然后西妥昔单抗和贝伐单抗治疗：SWOG S0536
6. PCN89 A COST EFFECTIVENESS ANALYSIS DEMONSTRATES THE BENEFITS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN SPAIN [O] . de Castro Carpeño J, Castro Gómez A, Walzer S 2009

机译：PCN89成本效益分析证明了患有晚期或复发性非小细胞肺癌的患者接受贝伐单抗加西沙丁胺和吉西他滨（BCG）与西妥昔单抗加长春新碱和西斯拉丁（CVC）的益处。

PCN14 AN INDIRECT COMPARISON OF THE EFFICACY OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) OR BEVACIZUMAB PLUS CARBOPLATIN AND PACLITAXEL (BCP) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)

著录项

引文网络

相似文献

相关主题

期刊订阅